E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
|
E.1.1.1 | Medical condition in easily understood language |
Longstanding inflammatory disease of the nerves leading to significant weakness, numbness and fatigue. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057645 |
E.1.2 | Term | Chronic inflammatory demyelinating polyradiculoneuropathy |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does initial treatment with both intravenous immunoglobulin and intravenous methylprednisolone lead to more frequent long-term remission (defined as sustained improvement without need for further treatment) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) compared to initial treatment with intravenous immunoglobulin alone? |
|
E.2.2 | Secondary objectives of the trial |
Compared to intravenous immunoglobulin alone, does initial combination treatment with intravenous immunoglobulin and intravenous methylprednisolone in chronic inflammatory demyelinating polyneuropathy (CIDP) patients lead to: 1. higher rates of improvement? 2. faster speed of improvement? 3. less healthcare costs? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Probable or definite CIDP according to the EFNS/PNS criteria 2010 (all CIDP phenotypes). 2) Age ≥ 18 years. 3a) Treatment naïve patients (no previous immune treatment for CIDP); or 3b) Previously immune-treated patients who have a relapse after a remission of at least 1 year; or 3c) Patients treated with subjective or objective improvement after a single loading course of IVIg in the last 3 months, and subsequent deterioration as judged by their treating physician. |
|
E.4 | Principal exclusion criteria |
1) Presence of IgM paraproteinemia, anti-MAG antibodies or CIDP-specific antibodies associated with poor treatment response to IVIg. 2) Use of drugs associated with a demyelinating neuropathy. 3) Use of any immunosuppressive or immunomodulatory drugs in previous 6 months (except for a single loading dose of IVIg within 3 months or low dose prednisolone (20 mg or less) during a short period (maximum duration of two weeks). 4) Known serious adverse events with previous IVIg or corticosteroid treatment. 5) One of more of the risk factors associated with increased risk of adverse events of IVIg or IVMP or conditions that could lead to unblinding of treatment (i.e. diabetes; IgA deficiency; gastric ulcers; psychosis; severe hypertension (180/110 mmHg or more on repeated measurements); hypocalcaemia (lower than 2.20 mmol/L, corrected for albumin); moderate or severe heart failure; severe cardiovascular disease (i.e. more than one myocardial infarction and or ischemic stroke); renal failure (glomerular filtration rate < 30 ml/min). 6) History of osteoporosis or osteoporotic fractures. 7) Known active malignancy, currently treated with chemotherapy or immunomodulatory drugs, or with a life expectancy of less than 1 year. . 8) Bodyweight more than 120 kg. 9) Pregnancy or nursing mother; intention to become pregnant during the course of the study; female patients of childbearing potential (from menarche until 1 year after the last period, surgical menopause or sterilization procedure) either not using or not willing to use a medically reliable method of contraception for the entire duration of the study. 10) Known cataract or cataract obvious on fundoscopy. 11) Current psychosis or past history of psychosis. 12) Poor dental status. 13) Known pulmonary embolism or other deep venous thrombosis in patient’s medical history, without current anticoagulant therapy. 14) Patient lacking capacity to consent to enter the trial. 15) Lack of written informed consent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is the number of patients in remission at 1 year after start of an 18 weeks treatment period.
Remission is defined as sustained improvement without receiving any further immune treatment (as defined below under treatment failure).
Improvement is defined as improvement by at least the minimal clinical important difference (MCID) on the inflammatory Rasch-Overall Disability Scale (I-RODS), and/or improvement of one or more points on the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale, at 18 weeks compared to baseline.
Sustained is defined as no deterioration between 18 weeks and 52 weeks, where deterioration is defined as worsening on the I-RODS by at least the MCID and/or on the INCAT disability scale by one or more points.
A patient will be considered as a treatment failure and therefore not in remission if they 1) receive additional immune treatment for CIDP (other than that in the protocol) during the 18-week intervention period, 2) have not improved at 18 weeks, 3) receive any immune treatment for CIDP for any reason between 18 and 52 weeks, or 4) do not show a sustained improvement at 52 weeks as defined above. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 year after the start of an 18 week treatment period. |
|
E.5.2 | Secondary end point(s) |
1) The number of patients with improvement on disability equal or more than the minimal clinically important difference (MCID) 2) Time to improvement (≥ MCID) on disability; 3) Mean change in disability; 4) Mean change in grip strength; 5) Mean change in muscle strength by MRC sum score; 6) Mean change in sensory impairment; 7) Mean change in fatigue; 8) Mean change in pain; 9) Mean change in health related quality of life (HRQL); 10) Number of (serious) adverse events (including corticosteroid associated adverse events); 11) Care use and overall healthcare-related costs. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will be assessed at 18 and 52 weeks, or earlier if a preliminary endpoint (treatment failure) is reached (i.e. additional treatment is started during the 18 week treatment period or between 18 and 52 weeks). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 2 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 30 |